PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney

Human Pathology

Volumn 38, Issue 9, 2007, Pages 1425-1431

  Vranić, Semir ^a   Bilalović, Nurija ^a   Lee, Lisa M J ^b   Krušlin, Božo ^c   Lilleberg, Stan L ^d   Gatalica, Zoran ^b  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d TRANSGENOMIC INC   (United States)

Author keywords

Adenoid cystic carcinoma; Breast; mTOR; PIK3CA; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; AGED; AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; ENZYME INACTIVATION; ENZYME REGULATION; EXON; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; KIDNEY METASTASIS; MASTECTOMY; NEPHRECTOMY; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; SOMATIC MUTATION; TUMOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTADENOCARCINOMA; DNA, COMPLEMENTARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MUTATION; PROMOTER REGIONS (GENETICS); PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 34547842097     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.03.021     Document Type: Article

References (18)

1. Sumpio B.E., Jennings T.A., Sullivan P.D., and Merino M.J. Adenoid cystic carcinoma of the breast. Ann Surg 205 (1987) 295-301
2. Azoulay S., Laé M., Fréneaux P., et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favourable outcome. Mod Pathol 18 (2005) 1623-1631
3. Page D.L. Adenoid cystic carcinoma of breast, a special histopathologic type with excellent prognosis. Breast Cancer Res Treat 93 (2005) 189-190
4. Herzberg A.J., Bossen E.H., and Walther P.J. Adenoid cystic carcinoma of the breast metastatic to the kidney. A clinically symptomatic lesion requiring surgical management. Cancer 68 (1991) 1015-1020
5. Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5 (2006) e1-e9
6. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
7. Sørlie E. Molecular portraits of breast cancer: tumor subtypes as distinct disease entities. Eur J Cancer 40 (2004) 2667-2675
8. Banerjee S., Reis-Filho J.S., Ashley S., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59 (2006) 729-3548
9. Saal L.H., Holm K., Maurer M., et al. PIK3CA mutations correlate with hormone receptors, node metastasis and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65 (2005) 2554-2559
10. Oda K., Stokoe D., Taketani Y., and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65 (2005) 10669-10673
11. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5 (2005) 921-929
12. Li S.Y., Rong M., Grieu F., and Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96 (2006) 91-95
13. Kane L.P., Shapiro V.S., Stokoe D., and Weiss A. Induction of NF-kappa B by the Akt/PKB kinase. Curr Biol 9 (1999) 601-604
14. St-Germain M.E., Gagnon V., Parent S., and Asselin E. Regulation of COX-2 protein expresion by Akt in endometrial cancer cells is mediated through NFκB/IκB pathway. Mol Cancer 3 (2004) 7
15. Cristofano A.D., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
16. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351 (2004) 2337-2338
17. Hotte S.J., Winquist E.W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23 (2005) 585-590
18. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46 (2006) 249-279